Data / Drug companies / Amantadine
Amantadine: 10 companies and 14 products in the FDA NDC directory
Amantadine is listed in the FDA National Drug Code Directory by 10 companies, with 14 products in commercial distribution. 10 of the products (71.4%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; capsule, coated pellets; capsule, and the newest product started marketing on January 19, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 10
- Products
- 14
- Generic (ANDA) products
- 10 (71.4%)
- Application numbers
- 4
- Routes
- Oral
- Brand names
- Gocovri
- openFDA record search
- api.fda.gov
Companies that list amantadine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Adamas Pharma, LLC | 2 | capsule, coated pellets | New drug applications (NDA) | August 24, 2017 |
| Alembic Pharmaceuticals Inc. | 2 | tablet; capsule | Generic drugs (ANDA) | October 20, 2020 |
| Alembic Pharmaceuticals Limited | 2 | capsule; tablet | Generic drugs (ANDA) | October 20, 2020 |
| Supernus Pharmaceuticals, Inc. | 2 | capsule, coated pellets | New drug applications (NDA) | August 24, 2017 |
| American Health Packaging | 1 | capsule | Generic drugs (ANDA) | May 1, 2019 |
| AvPAK | 1 | solution | Generic drugs (ANDA) | January 19, 2026 |
| Coupler LLC | 1 | tablet | Generic drugs (ANDA) | March 13, 2025 |
| NCS HealthCare of Ky, LLC DBA Vangard Labs | 1 | tablet | Generic drugs (ANDA) | October 20, 2020 |
| Proficient Rx LP | 1 | tablet | Generic drugs (ANDA) | October 20, 2020 |
| Xttrium Laboratories, Inc. | 1 | solution | Generic drugs (ANDA) | November 5, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 5 | 35.7% |
| Capsule, coated pellets | 4 | 28.6% |
| Capsule | 3 | 21.4% |
| Solution | 2 | 14.3% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 10 | 71.4% |
| New drug applications (NDA) | 4 | 28.6% |
Pharmacologic classes
| Class | Products |
|---|---|
| Influenza A M2 Protein Inhibitor | 14 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.